PAVmed Inc. (NASDAQ:PAVM) Shares Purchased by First Manhattan CO. LLC.

First Manhattan CO. LLC. boosted its holdings in PAVmed Inc. (NASDAQ:PAVM) by 16.7% during the fourth quarter, HoldingsChannel reports. The fund owned 700,000 shares of the company’s stock after buying an additional 100,000 shares during the period. First Manhattan CO. LLC. owned about 0.06% of PAVmed worth $439,000 at the end of the most recent quarter.

PAVmed Stock Down 0.8%

NASDAQ:PAVM opened at $0.67 on Monday. The stock’s fifty day moving average is $0.71 and its two-hundred day moving average is $0.77. PAVmed Inc. has a 52 week low of $0.55 and a 52 week high of $2.35. The stock has a market capitalization of $11.41 million, a price-to-earnings ratio of -0.15 and a beta of 1.11.

Wall Street Analyst Weigh In

Separately, Ascendiant Capital Markets upped their price objective on PAVmed from $19.00 to $19.50 and gave the company a “buy” rating in a report on Monday, April 21st.

PAVmed Profile

PAVmed Inc focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck.